Short answer: A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications under section 503A of the federal Food, Drug, and Cosmetic Act, based on valid prescriptions for individual, identified patients. State boards of pharmacy handle most day-to-day oversight. Compounded drugs made by a 503A pharmacy are not FDA-approved, which shapes how a telehealth brand can talk about them.
If you are building a telehealth brand that offers compounded medications, the first pharmacy term you will hear is 503A pharmacy. It sounds technical, and it is, but you do not need a pharmacy degree to understand it. You need to know what the label means, how it differs from a 503B outsourcing facility and a retail or brand-name pharmacy, and which questions to ask before you sign with a partner.
This guide walks through all of it in plain English, so you can have a confident conversation with your attorney, your platform and your pharmacy partners before your digital clinic goes live.
What is a 503A pharmacy?
Compounding is the practice of combining, mixing or altering ingredients to create a medication tailored to the needs of an individual patient. Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) describes the conditions under which a licensed pharmacist in a state-licensed pharmacy, or a physician, can compound drugs and qualify for certain exemptions from federal requirements.
The key condition is simple to state: a 503A pharmacy compounds based on the receipt of a valid, patient-specific prescription. That means a licensed prescriber has evaluated a specific patient and written a prescription for that patient. The pharmacy then prepares and dispenses the medication for that person, not for general stock or office use.
According to the FDA, drugs compounded under the conditions of section 503A are not subject to current good manufacturing practice (CGMP) requirements, and state boards of pharmacy generally have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities.
One point matters more than any other for marketing: the FDA states plainly that compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients. Every page, ad and email your brand publishes has to respect that fact.
503A vs 503B vs retail and brand-name pharmacies
Founders often hear three pharmacy categories in the same conversation. Here is how they compare at a high level.
| Feature | 503A compounding pharmacy | 503B outsourcing facility | Retail or brand-name pathway |
|---|---|---|---|
| What it dispenses | Compounded preparations for individual patients | Compounded drugs, often in larger batches | FDA-approved, commercially manufactured medications |
| Prescription requirement | Valid patient-specific prescription | May distribute by patient-specific prescription or in response to an order from a health care provider | Valid prescription for the patient |
| Primary oversight | State boards of pharmacy | FDA, with risk-based inspections | State boards of pharmacy |
| CGMP requirements | Not subject to CGMP when meeting 503A conditions | Subject to CGMP | Manufacturer follows CGMP; pharmacy follows state rules |
| FDA approval of the drug | Not FDA-approved | Not FDA-approved | FDA-approved product |
503B outsourcing facilities
A 503B outsourcing facility registers with the FDA, is subject to CGMP requirements and is inspected by the FDA on a risk-based schedule. Outsourcing facilities can compound with or without patient-specific prescriptions, which is why they commonly supply hospitals and clinics. Their products are still compounded drugs, so they are still not FDA-approved.
Retail and brand-name pathways
A retail or brand-name pathway dispenses commercially manufactured, FDA-approved medications. For a telehealth brand, this pathway usually looks like a licensed pharmacy that fills prescriptions for brand-name products and ships them to patients. Pricing, availability and insurance considerations work differently from compounding, and your marketing can describe these products differently, as long as it follows the rules for prescription drug promotion and platform ad policies.
Many telehealth brands use more than one pathway. A licensed provider decides what is appropriate for each patient, and the right pathway depends on the medication and the patient, not on what is easiest to sell.
Patient-specific prescriptions and the provider relationship
Because a 503A pharmacy compounds from patient-specific prescriptions, the provider evaluation is the foundation of the whole workflow. In a telehealth model, that usually looks like this: the patient completes an intake, a licensed provider reviews it (sometimes asynchronously, sometimes with a live visit, depending on state rules and the medication), and if the provider decides a prescription is appropriate, it is sent electronically to the pharmacy.
Your brand does not decide who gets a prescription. That line has to stay clear in your intake design, your support scripts and your marketing. Language like “get approved in minutes” or anything that suggests a prescription is automatic creates compliance risk and misrepresents how care works.
State board licensing for a 503A pharmacy
A 503A pharmacy is licensed by the board of pharmacy in the state where it operates. If it ships to patients in other states, it typically needs a nonresident pharmacy license or registration in each of those states, and requirements vary from state to state. This matters to you directly: your pharmacy partner must be licensed to dispense into every state where you plan to serve patients.
Ask for a current list of states where the pharmacy holds active licenses, and verify them through each state board’s license lookup. Licenses expire and change, so plan to recheck them periodically rather than only at signing.
Accreditation, PCAB and USP standards
USP 795, 797 and 800
The United States Pharmacopeia (USP) publishes the standards that most state boards reference for compounding quality:
- USP <795> covers nonsterile compounding, such as many capsules, creams and oral preparations.
- USP <797> covers sterile compounding, including injectable preparations. A revised version of this chapter became official on November 1, 2023, and it moved from the older low, medium and high risk levels to Category 1, 2 and 3 compounded sterile preparations.
- USP <800> addresses handling of hazardous drugs to protect patients, staff and the environment.
If your digital clinic offers injectable compounded medications, USP <797> compliance is one of the most important things to confirm with a pharmacy partner.
PCAB accreditation
The Pharmacy Compounding Accreditation Board (PCAB) program, administered by the Accreditation Commission for Health Care (ACHC), is a voluntary accreditation that evaluates a compounding pharmacy’s processes against USP <795>, <797> and <800>. ACHC offers separate sterile and nonsterile compounding accreditations. Accreditation is not a legal requirement in most places, but it is a meaningful signal that a third party has reviewed the pharmacy’s quality systems. Ask whether a partner holds it, for which compounding types, and when it renews.
Cold chain and shipping
Some compounded preparations, particularly many injectables, need to stay within a set temperature range from the pharmacy to the patient’s door. That is the cold chain. Ask each pharmacy partner:
- Which of your preparations require refrigerated shipping?
- What packaging do you use, and how long is it validated to hold temperature?
- How do you handle shipments to hot or cold climates and weekend deliveries?
- What happens if a package is delayed or arrives outside the safe range?
- What instructions do patients receive for storage after delivery?
Shipping issues are one of the most common sources of support tickets for a new telehealth brand, so clear answers here protect both patients and your customer experience.
How to evaluate a 503A pharmacy partner
- Confirm the license. Verify the home state license and every nonresident license you need through state board lookups.
- Review inspection history. Ask about recent state board inspections and any FDA inspections or regulatory actions, and search public records yourself.
- Check USP compliance. Ask how the pharmacy meets USP <795>, <797> and <800> for the preparations you plan to offer.
- Ask about accreditation. Find out whether the pharmacy holds PCAB accreditation and for which compounding types.
- Understand ingredient sourcing. Ask where active ingredients come from and whether certificates of analysis are available.
- Test the cold chain. Get written shipping and packaging procedures for temperature-sensitive products.
- Confirm integration. Make sure the pharmacy can receive e-prescriptions from your platform and share order and shipping status.
- Get the agreement reviewed. Have a healthcare attorney review the pharmacy agreement, including any business associate terms under HIPAA.
Questions to ask a pharmacy partner
- Are you operating as a 503A pharmacy, a 503B outsourcing facility, or both?
- Which states can you legally dispense into today?
- Do you hold PCAB accreditation, and for sterile, nonsterile or both?
- How do you document compliance with USP <797> for sterile preparations?
- What are your typical turnaround and shipping times, and how do you communicate delays?
- How do you handle adverse event reports, complaints and recalls?
- Who appears on the label, and how should our brand describe the pharmacy relationship?
- Will you sign a business associate agreement, if one is needed for our arrangement?
That label question matters. In its warning letters to telehealth companies, the FDA has flagged websites that implied the telehealth brand was the compounder, or that described compounded drugs as generic versions of, or the same as, FDA-approved products. The FDA has also cautioned against claiming a drug comes from an “FDA-approved” facility, since the agency does not approve pharmacies.
Marketing compounded medications the right way
Working with a 503A pharmacy changes what your marketing can say. The FDA has published guidance for telehealth companies on promoting compounded drugs, and a few rules show up again and again:
- Never call a compounded medication FDA-approved, and never imply the FDA reviewed it.
- Do not describe compounded drugs as generic versions of, or the same as, FDA-approved drugs.
- Do not claim compounded drugs produce the same results as approved alternatives.
- Do not imply your brand manufactures or compounds the drug when a pharmacy does.
- Make it clear that a licensed provider decides whether a prescription is appropriate.
Ad platforms add their own layer. Meta and Google both require telehealth and online pharmacy advertisers promoting prescription drugs to hold certification, with LegitScript as a recognized option. Our telehealth compliance checklist covers those rules in more detail.
How WellieMD helps
WellieMD is a white-label telehealth platform, often described as a digital clinic platform, that connects your brand to licensed providers, licensed 503A compounding pharmacies and brand-name pharmacy pathways. The platform includes branded intake, licensed provider review, e-prescribing, subscriptions, refills and lab workflows, is HIPAA-ready with a business associate agreement, and is LegitScript certified. That means fewer separate pharmacy relationships for you to source, vet and integrate on your own.
WellieMD was founded by Jessica Lynne White, BS, MSPT, a licensed physical therapist for 27 years, and the team includes a licensed pharmacist and five registered nurses. You can see the full feature set on our white-label telehealth platform page, and our guide on how much it costs to start a telehealth business explains where pharmacy costs fit in your budget. If you want a done-for-you team to handle brand, website and launch, GrowPro has launched 80+ telehealth brands. Either way, we build it with you.
Frequently asked questions
Is a 503A pharmacy regulated by the FDA?
The FDA sets the federal conditions in section 503A, but state boards of pharmacy generally have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities. The FDA can still act when a pharmacy does not meet 503A conditions or other federal requirements.
Are medications from a 503A pharmacy FDA-approved?
No. The FDA states that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before they reach patients. Your marketing must never describe them as FDA-approved or imply otherwise.
What is the main difference between 503A and 503B?
A 503A pharmacy compounds based on patient-specific prescriptions and is primarily overseen by state boards. A 503B outsourcing facility registers with the FDA, must follow CGMP requirements and can compound with or without patient-specific prescriptions. Products from both are compounded drugs.
Does a 503A pharmacy need a license in every state it ships to?
Generally, a pharmacy that ships across state lines needs a nonresident license or registration in each state where patients receive medications, though requirements vary. Always confirm your partner’s active licenses for every state you plan to serve.
Is PCAB accreditation required?
In most cases it is voluntary. PCAB accreditation, administered by ACHC, evaluates a pharmacy’s processes against USP compounding standards. Many founders treat it as a useful quality signal when comparing partners, alongside licensing and inspection history.
Choose your 503A pharmacy partner with confidence
A 503A pharmacy is a state-licensed compounder that works from patient-specific prescriptions, and its products are not FDA-approved. Once you understand that, the rest of your due diligence falls into place: verify licenses in every state, confirm USP compliance, ask about PCAB accreditation, test the cold chain and market accurately. That foundation keeps your digital clinic on solid ground. If you are still weighing ownership rules, read How to Start a Telehealth Business Without Being a Doctor next. When you are ready to talk pharmacy pathways for your brand, book a demo with WellieMD.
This guide is general information, not legal or medical advice. Prescription products require evaluation by a licensed provider. Compounded medications are not FDA-approved.
Sources
- U.S. Food and Drug Administration: Human drug compounding laws
- U.S. Food and Drug Administration: Compounding and the FDA, Questions and Answers
- U.S. Food and Drug Administration: FDA to Telehealth Companies, What to Know When Promoting Compounded Drugs
- United States Pharmacopeia: General Chapter 797, Pharmaceutical Compounding, Sterile Preparations
- USP-NF: Revised General Chapter 797 Published
- Accreditation Commission for Health Care: PCAB Accreditation